Longitudinal Study for Relapsing Polychondritis
NCT04919538 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2026-01-23
Summary
Relapsing polychondritis (RP) is a rare systemic inflammatory disease characterized by recurrent inflammation of cartilage including ears, nose, tracheobronchial tree, chest wall and joints. Less commonly, it can cause inflammation of eyes, vasculature, nervous system, skin and inner ear. The purpose of this study is to study the pathogenesis of RP.
Conditions
- Relapsing Polychondritis
- Vasculitis
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Peter Merkel, MD, MPH · University of Pennsylvania
-
Shubhasree Banerjee, MD · University of Pennsylvania
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-02-26
- Primary Completion
- 2030-01-31
- Completion
- 2030-01-31
Countries
- United States
Study Locations
More Related Trials
-
Cardiac Safe Transplants for Systemic Sclerosis
NCT03593902 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
NCT02626845 ·Status: TERMINATED ·Phase: PHASE4
-
Rilonacept in Subjects With Cardiac Sarcoidosis
NCT06660732 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
NCT05351554 ·Status: TERMINATED ·Phase: PHASE2
-
eGPA and Local Inflammation Within the Ear, Nose and Throat Area
NCT06298448 ·Status: RECRUITING
-
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
NCT01211977 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
NCT00584935 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
NCT00065390 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
NCT05444530 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
NCT02020889 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
NCT05104723 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
NCT01842386 ·Status: COMPLETED ·Phase: PHASE1
-
Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
NCT03145922 ·Status: RECRUITING
-
Belimumab With Rituximab for Primary Membranous Nephropathy
NCT03949855 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Belimumab Administered Subcutaneously to Healthy Subjects
NCT01583530 ·Status: COMPLETED ·Phase: PHASE1
-
Tocilizumab in Patients With Schnitzler's Syndrome
NCT03046381 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
NCT01140503 ·Status: TERMINATED ·Phase: NA
-
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
NCT03248531 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
NCT06012448 ·Status: COMPLETED ·Phase: PHASE4
-
Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis
NCT00033891 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid
NCT03295383 ·Status: RECRUITING ·Phase: PHASE3
-
Tocilizumab for Relapsing Polychondritis
NCT01104480 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis
NCT07012057 ·Status: WITHDRAWN ·Phase: PHASE2